Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

TherapeuticsMD Inc Stock Research

TXMD

3.33USD-0.09(-2.63%)Market Closed
Watchlist

Market Summary

USD3.33-0.09
Market Closed
-2.63%

TXMD Stock Price

TXMD RSI Chart

TXMD Valuation

Market Cap

35.2M

Price/Earnings (Trailing)

0.82

Price/Sales (Trailing)

0.55

EV/EBITDA

0.18

Price/Free Cashflow

0.98

TXMD Price/Sales (Trailing)

TXMD Profitability

EBT Margin

68.30%

Return on Equity

491.55%

Return on Assets

264.11%

Free Cashflow Yield

101.83%

TXMD Fundamentals

TXMD Revenue

Revenue Y/Y

-95.96%

Revenue Q/Q

-45%

TXMD Earnings

Earnings (TTM)

42.7M

Earnings Y/Y

-102.15%

Earnings Q/Q

33%

Price Action

52 Week Range

3.307.53
(Low)(High)

Last 7 days

-8.0%

Last 30 days

-11.2%

Last 90 days

-15.5%

Trailing 12 Months

-52.8%

TXMD Financial Health

Current Ratio

1.28

TXMD Investor Care

Shares Dilution (1Y)

20.86%

Diluted EPS (TTM)

4.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for TXMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-17
ZIEGLER JOSEPH
acquired
-
-
7,500
principal financial officer
2023-06-28
Rubric Capital Management LP
acquired
1,150,000
3.6797
312,525
-
2023-04-26
Walker Marlan D
sold
-2,517
3.6381
-692
chief executive officer
2023-04-26
Walker Marlan D
acquired
-
-
2,744
chief executive officer
2023-04-12
Walker Marlan D
sold
-4,275
3.6543
-1,170
chief executive officer
2023-04-12
Walker Marlan D
acquired
-
-
7,508
chief executive officer
2023-04-12
Donegan Michael C
acquired
-
-
50,000
prin. fin. and acctg. officer
2023-01-27
Donegan Michael C
sold
-249
5.09
-49.00
prin. fin. and acctg. officer
2023-01-26
Donegan Michael C
acquired
-
-
5,940
prin. fin. and acctg. officer
2023-01-26
Donegan Michael C
sold
-8,371
5.0796
-1,648
prin. fin. and acctg. officer

1–10 of 50

Which funds bought or sold TXMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-21
OSAIC HOLDINGS, INC.
added
584
12,634
14,571
-%
2023-08-15
WELLS FARGO & COMPANY/MN
reduced
-12.99
-69.00
1,462
-%
2023-08-15
Clearline Capital LP
added
8.57
303,289
1,876,130
0.11%
2023-08-15
HARBOUR INVESTMENTS, INC.
unchanged
-
3.00
33.00
-%
2023-08-14
Guardian Wealth Management, Inc.
unchanged
-
-
8.00
-%
2023-08-14
CITADEL ADVISORS LLC
new
-
499
499
-%
2023-08-14
Royal Bank of Canada
added
73.95
2,000
5,000
-%
2023-08-14
VANGUARD GROUP INC
unchanged
-
142,541
1,587,220
-%
2023-08-14
STATE STREET CORP
reduced
-0.01
11,139
124,127
-%
2023-08-14
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
15,540
173,040
-%

1–10 of 41

Latest Funds Activity

Are funds buying TXMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TXMD
No. of Funds

Schedule 13G FIlings of TherapeuticsMD

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 30, 2023
rubric capital management lp
19.57%
2,069,716
SC 13D/A
Aug 30, 2022
rubric capital management lp
18.27%
1,721,953
SC 13D/A
Jul 08, 2022
blackrock inc.
1.4%
122,138
SC 13G/A
Jun 03, 2022
beryl capital management llc
1.5%
126,229
SC 13G
Mar 23, 2022
smith robert j
5.38%
23,103,292
SC 13D/A
Feb 14, 2022
price t rowe associates inc /md/
0.1%
649,807
SC 13G/A
Feb 01, 2022
blackrock inc.
5.9%
24,894,812
SC 13G/A
Jul 07, 2021
flynn james e
4.90%
20,662,810
SC 13G
Feb 16, 2021
price t rowe associates inc /md/
6.2%
18,869,212
SC 13G/A
Feb 10, 2021
vanguard group inc
4.39%
13,165,644
SC 13G/A

Recent SEC filings of TherapeuticsMD

View All Filings
Date Filed Form Type Document
Aug 21, 2023
4
Insider Trading
Aug 21, 2023
3
Insider Trading
Aug 18, 2023
8-K
Current Report
Aug 14, 2023
8-K
Current Report
Aug 14, 2023
10-Q
Quarterly Report
Jul 19, 2023
4
Insider Trading
Jul 19, 2023
4
Insider Trading
Jul 19, 2023
4
Insider Trading
Jul 11, 2023
D
D
Jul 10, 2023
8-K
Current Report

Peers (Alternatives to TherapeuticsMD)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
517.3B
29.5B
5.22% 88.98%
79.61
17.53
1.53% 14.16%
421.5B
97.8B
-5.97% -1.12%
32.29
4.31
2.29% -28.92%
272.8B
58.3B
-1.68% 25.60%
17.88
4.63
2.00% -81.24%
191.9B
77.9B
-7.28% -24.56%
8.94
2.46
-23.04% -26.74%
150.1B
45.2B
-5.53% -15.83%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.68% 536.50%
-74
4.1K
-86.94% 71.24%
4.5B
4.6B
-12.08% -16.86%
-67.03
0.98
6.60% 42.04%
SMALL-CAP
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.5B
634.0M
-8.17% -19.68%
35.6
2.43
0.62% -24.59%
842.2M
109.5M
18.82% -27.78%
-5.87
7.69
-2.66% -32.13%
814.0M
244.3M
-8.50% 0.08%
4.13
3.33
-39.50% -4.99%
567.0M
453.3M
123.19% -68.11%
-0.46
1.25
-16.04% 55.90%
505.9M
977.9M
-17.56% -11.73%
15.52
0.52
3.78% -33.69%
106.7M
-
2.08% -28.79%
-3.22
2.72
- -
35.2M
-
-11.20% -52.83%
0.82
0.55
-19.54% 257.52%

TherapeuticsMD News

MarketWatch
TherapeuticsMD Inc. stock falls Tuesday, underperforms market.
MarketWatch,
13 hours ago
InvestorsObserver
The Pharma Letter
StreetInsider.com
Form 10-Q TherapeuticsMD, Inc. For: Jun 30.
StreetInsider.com,
36 days ago

Returns for TXMD

Cumulative Returns on TXMD

-31.0%


10-Year Cumulative Returns

-48.1%


7-Year Cumulative Returns

-60.3%


5-Year Cumulative Returns

-64.2%


3-Year Cumulative Returns

Risks for TXMD

What is the probability of a big loss on TXMD?

100%


Probability that TherapeuticsMD stock will be more than 20% underwater in next one year

99.6%


Probability that TherapeuticsMD stock will be more than 30% underwater in next one year.

96.9%


Probability that TherapeuticsMD stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if TherapeuticsMD was unfortunately bought at previous high price.

Drawdowns

Financials for TherapeuticsMD

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue---69,963,00069,235,33368,507,66767,780,00086,951,00090,851,00084,787,00072,487,00064,872,00058,196,00062,573,00057,951,00049,647,00038,834,00018,588,53516,272,54516,098,93715,134,93716,079,402
Gross Profit1.4%31,125,00030,688,00068,566,00045,543,00048,538,00067,407,00068,113,00071,169,00067,108,00054,540,00048,897,00044,923,00051,135,00049,664,00043,312,00034,428,00014,928,00013,407,00013,362,00012,753,00013,695,000
Operating Expenses-612.4%-9,997,0001,951,00067,375,000-7,194,00014,975,00054,166,00080,748,000210,154,000191,146,000188,437,000204,438,000210,248,537218,558,220213,686,098194,517,000179,361,869167,150,850157,014,725143,581,978126,532,660107,945,721
  S&GA Expenses-35.8%21,166,00032,960,00057,903,00045,805,00056,681,00074,270,00080,748,000112,189,000104,557,000102,280,000117,052,000102,301,481125,055,467136,555,918114,231,000156,789,394142,016,480130,095,799115,988,95494,757,03776,460,833
  R&D Expenses----5,512,0006,005,0006,436,0007,086,0008,060,0008,482,0009,213,00010,432,00012,470,01214,520,75016,743,11819,792,00022,113,17824,743,71126,577,72327,299,13831,520,90431,249,435
EBITDA-100.0%-47,859,00015,812,00034,325,00018,810,000-142,449,000-135,405,000-139,166,967-124,138,180-133,974,925-153,900,924-163,212,450-164,765,792-171,165,387-158,149,998------
EBITDA Margin-100.0%-0.680.230.390.20-1.65-1.56-1.53-1.46-1.85-2.37-2.80-2.63-2.95-3.19------
Interest Expenses0.4%-12,427,000-12,472,00013,545,0009,924,00012,609,00020,205,00025,068,00032,953,00033,115,00032,546,00028,581,00026,633,36824,552,37321,553,98217,382,00013,811,00710,265,0796,767,8524,677,8345,168,9182,125,528
Earnings Before Taxes15.6%-67,460,000-79,919,0001,074,000-11,823,000-30,018,000-57,797,000-79,305,000-171,542,000-156,734,000-166,058,000-183,524,000-190,872,515-190,227,108-193,487,625-176,145,000-166,100,466-169,739,175-147,721,706-132,617,160-114,653,509-93,712,848
EBT Margin-100.0%-0.680.02-0.10-0.29-2.11-1.98-1.89-1.85-2.29-2.83-3.28-3.04-3.34-3.55------
Net Income-72.9%42,720,000157,415,000111,997,000-8,665,000-27,120,000-182,053,000-172,415,000-171,542,000-156,734,000-166,058,000-183,524,000-190,872,000-190,227,000-193,488,000-176,145,000-166,101,000-169,739,000-147,721,000-132,617,000-114,653,000-93,713,000
Net Income Margin-100.0%-2.251.60-0.10-0.29-2.11-1.98-1.89-1.85-2.29-2.83-3.28-3.04-3.34-3.55------
Free Cashflow-100.0%-18,530,0009,359,000-103,429,000-122,661,000-133,852,000-142,727,000-133,658,959-129,603,000-158,988,174-159,677,408-180,311,148-173,468,453-168,854,278-168,147,880------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-9.9%54.0060.0090.00134146133169210211239182177206269266250247182212237172
  Current Assets-20.7%20.0025.0055.0087.0099.0084.00119160160187128122149212208192216153187212167
    Cash Equivalents0%49.0049.0038.0038.0065.0065.0079.0010511113880.0080.00114170161155183123162190154
  Inventory----7.006.009.008.007.008.007.008.0010.0010.0015.0012.0011.007.005.003.002.002.00
  Net PPE-32.8%0.000.000.001.001.001.001.001.002.002.002.002.002.002.003.002.001.001.000.000.000.00
Liabilities-18.4%22.0028.0055.0018217227426326726024930629330031425727123812111410394.00
  Current Liabilities-25.7%14.0019.0047.0017416426525386.0076.0061.0059.0047.0046.0062.0053.0067.0042.0045.0041.0029.0021.00
    LT Debt, Current----94.0091.0020318815.0010.005.00-----------
    LT Debt, Non Current--------17217517923823724424319519419474.0073.0073.0073.00
Shareholder's Equity-2.6%31.0032.0035.00--26.07-140-93.62-------9.00-8.0061.0098.0013478.00
  Retained Earnings-0.3%-945-942-939-1,017-988-1,100-1,051-1,008-960-918-878-836-804-752-695-645-614-558-519-479-444
  Additional Paid-In Capital0.2%977975974969962960958951912908755721710707704625622619617614522
Shares Outstanding10.8%11.0010.009.009.009.009.009.008.008.007.006.005.005.005.005.005.005.005.005.005.004.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations93.5%35,85918,5309,359-15,848-28,814-34,625-55,133-133,492-129,318-158,740-159,471-179,931-172,105-166,665-165,718-143,045-150,890-125,325-106,811-99,472-82,088
  Share Based Compensation-18.0%8,1989,99411,57213,93316,95317,22918,12514,95610,77711,27010,67911,32510,82710,46110,68210,1339,7589,4988,6628,2407,966
Cashflow From Investing----355140,802-1,984-1,997-2,223-1,203-1,283-1,593-1,598-21,817-22,857-23,669-23,892-3,849-22,882-21,983-21,497-21,178-915
Cashflow From Financing-Infinity%-220,412--235,206-103,905-91,82528,603129,552159,902128,186127,85280,725126,053125,956237,549188,827112,226202,232162,843162,787162,357140,915

TXMD Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total revenue, net$ 437$ 348$ 853$ 1,043
Cost of revenue 348 1,043
Gross profit43708530
Operating expenses:    
Selling, general and administrative2,78114,5755,83732,121
Depreciation & amortization128282155611
Total operating expenses2,90914,8575,99232,732
Loss from operations(2,472)(14,857)(5,139)(32,732)
Other (expense) income:    
Interest expense and other financing costs(45)0(95)0
Miscellaneous income (expense)103(16)510(16)
Total other income (loss), net58(16)415(16)
Income (loss) from continuing operations before income taxes(2,414)(14,873)(4,724)(32,748)
Income (loss) from discontinued operations, net of income taxes0127,154(1,293)96,008
Net income (loss)$ (2,414)$ 112,281$ (6,017)$ 63,260
Income (loss) per common share, basic:    
Continuing operations$ (0.24)$ (1.7)$ (0.47)$ (3.77)
Discontinued operations, net014.53(0.13)11.06
Net income (loss) per common share, basic(0.24)12.83(0.6)7.29
Income (loss) per common share, diluted:    
Continuing operations(0.24)(1.7)(0.47)(3.77)
Discontinued operations, net014.53(0.13)11.06
Net income (loss) per common share, diluted$ (0.24)$ 12.83$ (0.6)$ 7.29
Weighted average common shares, basic10,2198,7509,9888,682
Weighted average common shares, diluted10,2198,7509,9888,682
Comprehensive income (loss):    
Net income (loss)$ (2,414)$ 112,281$ (6,017)$ 63,260
Other comprehensive income
Comprehensive income (loss):$ (2,414)$ 112,281$ (6,017)$ 63,260

TXMD Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash$ 13,729$ 38,067
Restricted cash 11,250
Royalty receivable, current portion841 
Prepaid and other current assets5,0436,034
Total current assets19,61355,351
Fixed assets, net3978
License rights and other intangible assets, net6,7676,943
Right of use assets7,2287,580
Royalty receivable, long term19,78820,253
Other non-current assets254253
Total assets53,68990,458
Current liabilities:  
Accounts payable1,5082,162
Accrued expenses and other current liabilities11,48418,846
Current liabilities of discontinued operations1,37225,831
Total current liabilities14,36446,839
Operating lease liabilities6,9397,369
Other non-current liabilities1,1891,107
Total liabilities22,49255,315
Commitments and contingencies (Note 7)
Stockholders' equity (deficit):  
Common stock, par value $0.001; 32,000 and 12,000 shares authorized, 10,575 and 9,498 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively119
Additional paid-in capital976,566974,497
Accumulated deficit(945,380)(939,363)
Total stockholders' equity31,19735,143
Total liabilities and stockholders' equity$ 53,689$ 90,458
Hugh O'Dowd
420
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.